News & Updates

A once-weekly subcutaneous dose of the GLP-1* receptor agonist dulaglutide successfully controlled glycaemic levels in youths with type 2 diabetes (T2D) being treated with lifestyle modification with or without metformin or insulin, results of the multinational, phase III AWARD-PEDS** study showed.

Regardless of the use of medication, levels of low-density lipoprotein cholesterol (LDL-C) appear to be appropriately managed in older type 2 diabetes mellitus (T2DM) patients, contributing to the prevention of coronary artery disease (CAD), a recent study has found.

Renal composite outcomes (RCO) appear to be less favourable among type 2 diabetes (T2D) patients with chronic kidney disease (CKD) treated with insulin and sodium-glucose cotransporter 2 inhibitors (SGLT2i), a recent Japan study has found.

Use of sodium–glucose cotransporter-2 inhibitors (SGLT-2i) as first-line treatment for type 2 diabetes (T2D) delivers a comparable risk for myocardial infarction (MI), stroke, and mortality; a lower risk for hospitalization for heart failure (HHF)/mortality and HHF; and a similar safety profile, except for a higher risk for genital infections, when compared to treatment with metformin, a study has found.

A novel artificial intelligence platform that integrates multidimensional data to deliver precision nutrition and health recommendations not only helps to induce remission in type 2 diabetes but also to normalize a range of glycaemic and extraglycaemic parameters, as shown in a study presented at the 82nd American Diabetes Association (ADA) Scientific Sessions.

Higher consumption of dairy products is associated with a lower risk of type 2 diabetes (T2D) among US adults, according to a nationally representative study presented at ADA 2022.